GE Healthcare announced this week that it would be teaming up with the American College of Cardiology to push forward artificial intelligence and digital technologies in cardiac care.
The company says it will lend its perspective to the ACC’s Applied Health Innovation Consortium, a collaboration of patient advocates and academic, clinical, industry and technology partners aimed at clinically transforming health care.
” We’re excited to have GE Healthcare join forces with the Applied Health Innovation Consortium, ” stated Dr. John Rumsfeld, ACC chief innovation officer and chief science and quality officer, in a statement.
“In our mission to transform cardiovascular care and improve cardiovascular health, GE Healthcare is a great collaborator to help construct a roadmap for AI and digital technology that bridges gaps in clinical care, ” added Rumsfeld.
WHY IT MATTERS
According to the press release, the consortium hopes to specify challenges, develop AI models and put research results to practice through implementation in clinical workflows.
The collaboration will start by addressing atrial fibrillation management, along with coronary artery disease, valvular heart disease and heart failure.
Additionally, it intends to identify priorities and make progress in particular approaches to impact care – particularly around AI-driven services, such as image interpretation, risk prediction and decision support.
And it will do this, say the associations, with the help of GE Healthcare’s product development power and the ACC’s thought leadership.
As the announcement notes, cardiology clinicians use GE Healthcare’s AI software, hosted on its Edison platform, to diagnose and treat more than 145 million hearts every year.
“We are willing to help shape the heart care pathway from early detection to treatment to follow up at home by combining our experience in AI and electronic technologies with high clinical leadership to advance risk prediction and decision-making aid, ” said GE Healthcare Chief Technology Scientist for Cardiology Solutions Eigil Samset in a statement.
THE LARGER TREND
The news of GE Healthcare joining the Consortium follows consequences of a trial published this past month from the Mayo Clinic signaling the possible for AI-guided heart disease detection, especially with regard to low ejection fraction.
“The AI-enabled EKG facilitated the diagnosis of patients with low ejection fraction in a real life setting by identifying people who formerly would have slipped through the cracks, ” said Dr. Peter Noseworthy, a Mayo Clinic cardiac electrophysiologist who was the senior author on the study.
The trial was only the most recent attempt at harnessing the power of AI to address cardiovascular disease, especially around diagnostics. In 2020, the FDA approved marketing authorization for AI-enabled cardiac ultrasound software to assist in diagnosis for nonexpert providers.
ON THE RECORD
“Ultimately, this will enable precision wellbeing, which is doing the right thing, at the ideal time for each patient, at scales with the ultimate objective to provide improved results, delivered to more people, more cost effectively, ” said GE’s Samset about the new ACC project.